<div id="readability-page-1"><h3>Valentine's Day Sale - 70% Off</h3><ul><li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions </li><li> Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential</li></ul>The latest update is out from Sino Biopharmaceutical ( (HK:1177) ). Sino Biopharmaceutical’s subsidiary LaNova Medicines has completed patient enrollment in a Phase III registrational trial of tecotabart vedotin (LM-302), an antibody-drug conjugate targeting CLDN18.2 for third-line and later treatment of CLDN18.2-positive advanced gastric and gastroesophageal junction adenocarcinoma, marking the world’s first CLDN18.2 ADC to reach this milestone. Early clinical data presented at a major oncology meeting show high response and disease control rates for LM-302 in combination with toripalimab, and the program is being expanded with another planned Phase III first-line trial in China and supported by Breakthrough Therapy and Orphan Drug designations, underscoring Sino Biopharmaceutical’s push to strengthen its innovative oncology portfolio and global competitiveness. These developments highlight the Group’s strategy to accelerate clinical translation and commercialization of LM-302, backed by its industrial resources and regulatory recognitions in both China and the U.S. The advancement of LM-302 could provide new treatment options for patients with low CLDN18.2 and low PD-L1 expression, potentially reshaping the treatment landscape for difficult-to-treat gastrointestinal cancers and enhancing value for patients and other stakeholders. The most recent analyst rating on (HK:1177) stock is a Hold with a HK$7.50 price target. To see the full list of analyst forecasts on Sino Biopharmaceutical stock, see the HK:1177 Stock Forecast page. More about Sino Biopharmaceutical Sino Biopharmaceutical Limited is a Hong Kong-listed pharmaceutical group focused on innovative oncology treatments and other therapeutic areas, operating through subsidiaries including LaNova Medicines. The company develops and commercializes advanced drug modalities such as antibody-drug conjugates, aiming to expand its presence in high-value cancer segments in China and globally. YTD Price Performance: 4.85% Average Trading Volume: 65,700,656 Technical Sentiment Signal: Buy Current Market Cap: HK$115.9B See more insights into 1177 stock on TipRanks’ Stock Analysis page.</div>

159837

159859

512290

516500

01177

159102

159849

Sino Biopharmaceutical’s subsidiary, LaNova Medicines, has completed Phase III enrollment for tecotabart vedotin (LM-302), the first CLDN18.2 ADC to reach this milestone. This trial targets advanced gastric and gastroesophageal junction adenocarcinoma. Early data shows promising response rates, and a Phase III first-line trial is planned in China. The company aims to enhance its oncology portfolio and global competitiveness, with regulatory support in China and the U.S. The current analyst rating for Sino Biopharmaceutical (HK:1177) is a Hold with a price target of HK$7.50.

Sino Biopharm’s CLDN18.2 ADC Becomes First to Complete Phase III Enrollment